This protocol details the evaluation of antiviral candidates in vitro against MERS-CoV, suggesting that cytotoxicity assessments are included.
The following is a protocol for live virus antiviral screening against MERS-CoV EMC2012 in vitro. Cells are prophylactically treated with antiviral candidates that have been serially diluted to investigate activity, via IC50 values generated via analysis of immunofluorescent staining, against MERS-CoV. You may opt to remove PgP inhibitor in the assay. You may opt to use VeroE6 cells rather than Vero-TMPRSS2 cells. Each live virus screening assay is accompanied by a matching cytotoxicity screening assay in uninfected cells to investigate drug toxicity.
No takes yet. Share an insight, caveat, or question.
Briana L McGovern (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: